Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents.
about
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicityModes of resistance to anti-angiogenic therapyPolysaccharides from the root of Angelica sinensis protect bone marrow and gastrointestinal tissues against the cytotoxicity of cyclophosphamide in mice.Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcomaAntibody-drug conjugates as novel anti-cancer chemotherapeuticsMetronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistanceRole of cancer microenvironment in metastasis: focus on colon cancerIdentification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis.Specialization of tumour vasculature.Heterogeneous vascular dependence of tumor cell populationsTyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo.Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myelomaAngiogenesis inhibitors in the treatment of prostate cancer.Angiogenesis inhibition in prostate cancer: current uses and future promises.VEGF Expression to Support Targeted Therapy in Ovarian Surface Epithelial NeoplasmsCombining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials.Therapeutic strategies with oral fluoropyrimidine anticancer agent, S-1 against oral cancer.A highly recurrent RPS27 5'UTR mutation in melanoma.Targeting multiple angiogenic pathways for the treatment of neuroblastoma.A role for survivin in chemoresistance of endothelial cells mediated by VEGFAngiogenesis inhibitors: current strategies and future prospects.Immunotherapy of hepatoma with a monoclonal antibody against murine endoglin.Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis.Bone marrow angiogenesis and progression in multiple myeloma.Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles.The biology of the combretastatins as tumour vascular targeting agents.Normalization of tumor microenvironment by neem leaf glycoprotein potentiates effector T cell functions and therapeutically intervenes in the growth of mouse sarcoma.Antiangiogenic agents targeting vascular endothelial growth factor and its receptors in clinical development.Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice.Dual targeting of tumor angiogenesis and chemotherapy by endostatin-cytosine deaminase-uracil phosphoribosyltransferase.Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach.Molecular targets in the inhibition of angiogenesis.A new chemical inhibitor of angiogenesis and tumorigenesis that targets the VEGF signaling pathway upstream of RasTumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapyMeasuring tumour vascular response to antivascular and antiangiogenic drugs.Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancerPeptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapyCapecitabine combined with (-)-epigallocatechin-3-gallate inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenograftsEstablishing a link between oncogenes and tumor angiogenesisMetronomic dosing of chemotherapy: applications in pediatric oncology.
P2860
Q24561642-04C2DAD2-8075-4CD5-8959-EB5B74B2081AQ24608005-B67F3BF2-C0C7-4F52-93B3-920569D14533Q25256110-FC5F1C60-649F-484E-A984-ABCEDD443D62Q26747666-DB295A38-21D5-40C4-B560-D9C5AACCA8D9Q26800175-C2095776-FFC9-46A9-BA13-26EA6384000AQ27023579-9ED374EB-3E79-4B81-8731-3EA14A41F96BQ28239062-4AE7D7C9-E61D-4C7D-9223-9083B2C9C4E8Q30854194-A2E3A7FB-AC03-4EEB-887C-F22F54C2728AQ30896811-88EA7E11-AF6F-49FC-AFFF-CD011DF3E80DQ33181864-363531C2-21E6-4875-806E-15F335432D6CQ33279184-C34C9575-38DE-41C6-9C4E-9D5D9BD7DAE9Q33408052-07144D03-ADC8-4F5D-BC78-7868753B8DECQ33611121-76121766-64F3-43A6-949C-A39B83EB67B5Q33652297-D1844776-EDC8-4665-B366-344727C482B5Q33741593-D8DA9BB2-57E6-40ED-BA52-C07CDCAADA6DQ33802617-D728B14C-6D88-4974-B9ED-46DEDF4A090EQ33884698-033D8612-6D42-4D0E-B812-229677F911F8Q33917519-779FEAFA-8905-4C45-B8BF-CDDB9D40879CQ33995832-42C4FFC3-02FC-45EB-8B1E-65EC2511A6C7Q34047896-D958515F-9840-4374-8E94-A57B2D38327BQ34056376-61F47EAF-3956-45CE-9AC8-006F498FEB08Q34098560-EABFC90C-E883-4031-9F40-0BACD4D05787Q34130552-3FC7C9EA-8E74-4658-8F15-D71691651C23Q34292940-D2B0941D-13BF-4EDB-814A-7D137D936741Q34403657-071D2589-B2C2-4AE7-A581-299D9C3E371AQ34680614-6876FB39-287E-4145-974A-7521F77D673CQ34778932-51F8B258-F3F3-4AA2-A205-7C50D3073617Q34974876-EAD2AAEC-992F-42DE-B865-672CCA267343Q35157425-B52A829C-87F7-4DDC-A4DE-C905330E55E1Q35161745-8A0F21A9-2612-4A9E-B744-AB5F8AAF563DQ35175287-68B31523-7837-4F60-B4FC-B8BC4C919FA3Q35186667-A4E5517B-386B-4ED5-A6A1-68E23184106CQ35572415-54765DA8-7A89-457D-A7C7-6269A29595A8Q35748830-9BE54E82-1CEC-4118-A53C-464F2B470A0CQ35904992-F882C484-CB77-4ED1-94A8-A1B6CB64A6BEQ35966791-A6E5E004-9FB6-4AD5-BA20-FA7B28B1EDBFQ36116250-68F4F548-EE70-4051-8FEA-E82B4090404FQ36224291-38D08E06-AAD7-4FEF-B68C-1B1F382C1B2AQ36438366-D104013F-BC20-4C8C-9935-2F9CD0594024Q36508092-14B60ACA-06AD-4744-8001-D77BBF149F56
P2860
Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents.
description
1991 nî lūn-bûn
@nan
1991 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Inhibition of tumor angiogenes ...... nti-cancer therapeutic agents.
@ast
Inhibition of tumor angiogenes ...... nti-cancer therapeutic agents.
@en
Inhibition of tumor angiogenes ...... nti-cancer therapeutic agents.
@nl
type
label
Inhibition of tumor angiogenes ...... nti-cancer therapeutic agents.
@ast
Inhibition of tumor angiogenes ...... nti-cancer therapeutic agents.
@en
Inhibition of tumor angiogenes ...... nti-cancer therapeutic agents.
@nl
prefLabel
Inhibition of tumor angiogenes ...... nti-cancer therapeutic agents.
@ast
Inhibition of tumor angiogenes ...... nti-cancer therapeutic agents.
@en
Inhibition of tumor angiogenes ...... nti-cancer therapeutic agents.
@nl
P2860
P356
P1433
P1476
Inhibition of tumor angiogenes ...... nti-cancer therapeutic agents.
@en
P2093
P2860
P356
10.1002/BIES.950130106
P407
P577
1991-01-01T00:00:00Z